Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MBRX – Moleculin Biotech Inc

Moleculin Biotech, Inc.
MBRX
$0.3019
Name : Moleculin Biotech, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,275,639.00
EPSttm : -4.99
finviz dynamic chart for MBRX
Moleculin Biotech, Inc.
$0.3019
3.30%
$0.0103

Float Short %

8.79

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.69

EPS Last/This Y

1.04

EPS This/Next Y

0.43

Price

0.3

Target Price

7

Analyst Recom

1

Performance Q

-70.97

Relative Volume

1.28

Beta

1.41

Ticker: MBRX




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02MBRX0.9001N/AN/A0
2025-06-03MBRX0.8431N/AN/A0
2025-06-04MBRX0.6675N/AN/A0
2025-06-05MBRX0.69N/AN/A0
2025-06-06MBRX0.67N/AN/A0
2025-06-09MBRX0.6899N/AN/A0
2025-06-10MBRX0.664N/AN/A0
2025-06-11MBRX0.684N/AN/A0
2025-06-12MBRX0.6607N/AN/A0
2025-06-13MBRX0.654N/AN/A0
2025-06-16MBRX0.6821N/AN/A0
2025-06-17MBRX0.6564N/AN/A0
2025-06-18MBRX0.5692N/AN/A0
2025-06-20MBRX0.2575N/AN/A0
2025-06-23MBRX0.2723N/AN/A0
2025-06-24MBRX0.3035N/AN/A0
2025-06-25MBRX0.294N/AN/A0
2025-06-26MBRX0.3203N/AN/A0
2025-06-27MBRX0.3167N/AN/A0
2025-06-30MBRX0.3019N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02MBRX0.90- - -5.28
2025-06-03MBRX0.84- - -5.28
2025-06-04MBRX0.67- - -5.28
2025-06-05MBRX0.69- - -5.28
2025-06-06MBRX0.66- - -5.28
2025-06-09MBRX0.67- - -5.28
2025-06-10MBRX0.66- - -5.28
2025-06-11MBRX0.68- -9.9-5.28
2025-06-12MBRX0.67- 2.8-5.28
2025-06-13MBRX0.64- 1.8-5.28
2025-06-16MBRX0.68- -20.0-5.28
2025-06-17MBRX0.66- 3.7-5.28
2025-06-18MBRX0.58- 12.3-5.28
2025-06-20MBRX0.27- 139.8-5.28
2025-06-23MBRX0.27- - -5.28
2025-06-24MBRX0.30- - -5.28
2025-06-25MBRX0.29- - -5.28
2025-06-26MBRX0.32- - -5.28
2025-06-27MBRX0.31- - -5.28
2025-06-30MBRX0.30- - -5.28
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02MBRX0.000.997.01
2025-06-03MBRX0.000.997.01
2025-06-04MBRX0.000.997.01
2025-06-05MBRX0.000.997.01
2025-06-06MBRX0.000.997.01
2025-06-09MBRX0.000.997.01
2025-06-11MBRX0.000.994.30
2025-06-12MBRX0.000.994.30
2025-06-13MBRX0.000.994.30
2025-06-16MBRX0.000.994.30
2025-06-17MBRX0.000.994.30
2025-06-18MBRX0.000.994.30
2025-06-19MBRX0.000.994.30
2025-06-20MBRX0.000.994.30
2025-06-24MBRX00.994.30
2025-06-25MBRX00.994.30
2025-06-26MBRX00.9913.78
2025-06-27MBRX00.9913.78
2025-06-30MBRX81.600.998.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.69

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

81.6

Institutional Transactions

0.99

Beta

1.41

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

2

Growth Score

20

Sentiment Score

21

Actual DrawDown %

99.8

Max Drawdown 5-Year %

-99.8

Target Price

7

P/E

Forward P/E

PEG

P/S

P/B

101.65

P/Free Cash Flow

EPS

-5.8

Average EPS Est. Cur. Y​

-5.28

EPS Next Y. (Est.)

-4.85

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.28

Return on Equity vs Sector %

-55331

Return on Equity vs Industry %

-55311.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Moleculin Biotech, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 17
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
stock quote shares MBRX – Moleculin Biotech Inc Stock Price stock today
news today MBRX – Moleculin Biotech Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MBRX – Moleculin Biotech Inc yahoo finance google finance
stock history MBRX – Moleculin Biotech Inc invest stock market
stock prices MBRX premarket after hours
ticker MBRX fair value insiders trading